Overall impact
B (67)

Commentary

NovoCure is a strong overall performer. With a 'B' rating of 66.8 for overall impact (76th percentile compared to all companies), NovoCure ranks 75th out of 155 industry peers, behind American Shared Hospital Services, Accuray, BioSig Technologies and 71 others, and ahead of Hologic, Avinger, Adm Tronics Unlimited and 77 others. On top material causes for NovoCure's industry (Healthcare Equipment), NovoCure performs well in Access to Affordable Healthcare (90.2 score), Technology Innovation (87.7), Sanitation Access (86.2) and 1 other cause where it received an 'A' score and performs poorly in Improved Mental Health (38.6 score), Fair Labor Practices (38.7) and Humane Treatment of Animals (16.9).
Impact
Cause NVCR
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
1,605
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Equipment
SASB industry
Medical Equipment & Supplies
Headquarters
Switzerland
Share classes
NVCR
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Material causes
Ethos considers the following causes material for NovoCure, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.